Deborah Doroshow, MD, PhD
Assistant Professor Adjunct; Academic Affiliate in the History of Medicine
Research & Publications
Biography
Coauthors
Selected Publications
- A comparative analysis of needs and role of patient navigation among early-phase cancer clinical trial participants and non-participants at a single cancer center.Doroshow D, Sheng T, Aryeh B, Conner R, Loehle J, Lucas N, Padilla M, Pappalardo R, Fromm K, Smith C. A comparative analysis of needs and role of patient navigation among early-phase cancer clinical trial participants and non-participants at a single cancer center. Journal Of Clinical Oncology 2024, 42: e23127-e23127. DOI: 10.1200/jco.2024.42.16_suppl.e23127.
- Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).Oh D, Lugowska I, Stroyakovskiy D, Jung K, Dumas O, Penkov K, Dechaphunkul A, Oaknin A, Kim S, Starling N, Chewaskulyong B, Charonpongsuntorn C, Doroshow D, Hsiao S, Hung Y, Jung L, Kuptsova-Clarkson N, Michelini F, Puvvada S, Meric-Bernstam F. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). Journal Of Clinical Oncology 2024, 42: 4090-4090. DOI: 10.1200/jco.2024.42.16_suppl.4090.
- Optimizing care in early phase cancer trials: The role of palliative careCrowley F, Sheppard R, Lehrman S, Easton E, Marron T, Doroshow D, Afezolli D. Optimizing care in early phase cancer trials: The role of palliative care. Cancer Treatment Reviews 2024, 128: 102767. PMID: 38776612, DOI: 10.1016/j.ctrv.2024.102767.
- C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysisFujiwara Y, Karol A, Joshi H, Reford E, Izadmehr S, Doroshow D, Galsky M. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. Critical Reviews In Oncology/Hematology 2024, 197: 104352. PMID: 38614269, PMCID: PMC11219184, DOI: 10.1016/j.critrevonc.2024.104352.
- Abstract CT162: Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumorGarralda E, Boni V, Baz D, Chaudhry A, Bazo I, Gutierrez M, Malhotra J, Alonso C, Gambardella V, Chisamore M, Zhou R, Tea M, Doroshow D. Abstract CT162: Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor. Cancer Research 2024, 84: ct162-ct162. DOI: 10.1158/1538-7445.am2024-ct162.
- An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesisLaMarche N, Hegde S, Park M, Maier B, Troncoso L, Le Berichel J, Hamon P, Belabed M, Mattiuz R, Hennequin C, Chin T, Reid A, Reyes-Torres I, Nemeth E, Zhang R, Olson O, Doroshow D, Rohs N, Gomez J, Veluswamy R, Hall N, Venturini N, Ginhoux F, Liu Z, Buckup M, Figueiredo I, Roudko V, Miyake K, Karasuyama H, Gonzalez-Kozlova E, Gnjatic S, Passegué E, Kim-Schulze S, Brown B, Hirsch F, Kim B, Marron T, Merad M. An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis. Nature 2023, 625: 166-174. PMID: 38057662, PMCID: PMC11189607, DOI: 10.1038/s41586-023-06797-9.
- Abstract B040: NCI 10129: A Phase 2 Study of the PARP inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumorsCecchini M, Pilat M, Uboha N, Azad N, Cho M, Davis E, Ahnert J, Tinoco G, Shapiro G, Khagi S, Powers B, Groisberg R, Drappatz J, Chen L, Das B, Bao X, Li J, Patel A, Niger M, Doroshow D, Durecki D, Boerner S, Bindra R, Ivy P, Shyr Y, LoRusso P. Abstract B040: NCI 10129: A Phase 2 Study of the PARP inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant advanced solid tumors. Molecular Cancer Therapeutics 2023, 22: b040-b040. DOI: 10.1158/1535-7163.targ-23-b040.
- Abstract C030: HARMONi-3: A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancerRiess J, Lu S, Naidoo J, Kuruvilla S, Hung A, Khaled A, Doroshow D. Abstract C030: HARMONi-3: A randomized, controlled, multiregional Phase 3 study of ivonescimab combined with chemotherapy versus pembrolizumab combined with chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer. Molecular Cancer Therapeutics 2023, 22: c030-c030. DOI: 10.1158/1535-7163.targ-23-c030.
- Abstract LB_A14: Factors associated with enrollment, participation, and survival of patients on early phase cancer clinical trialsBaldwin E, Van Hyfte G, Lucas N, Wu K, Shelton G, Aird S, Chung G, Fazilov G, Fitzgerald L, Hapanowicz O, Holley K, King P, Lu A, Melukkaran N, Lucas M, Urena I, Wawrzyniak A, Posner M, Galsky M, Marron T, Doroshow D. Abstract LB_A14: Factors associated with enrollment, participation, and survival of patients on early phase cancer clinical trials. Molecular Cancer Therapeutics 2023, 22: lb_a14-lb_a14. DOI: 10.1158/1535-7163.targ-23-lb_a14.
- A case of urticarial vasculitis associated with atezolizumabYoung J, Rivera-Oyola R, Poplausky D, Suemitsu Y, Kim R, Doroshow D, Gulati N. A case of urticarial vasculitis associated with atezolizumab. JAAD Case Reports 2023, 43: 30-33. PMID: 38162407, PMCID: PMC10757233, DOI: 10.1016/j.jdcr.2023.09.042.
- EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung CancerDesland F, Fitzgerald B, Sheppard R, Van Hyfte G, Shimkus M, Rohs N, Veluswamy R, Rolfo C, Marron T, Smith C, Gomez J, Doroshow D. EP12.01-10 Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2023, 18: s644. DOI: 10.1016/j.jtho.2023.09.1225.
- cfDNA NGS for Identification of Primary and Acquired Resistance in Patients With Lung Cancer and EGFR MutationsPeleg A, Del Re M, Raphael A, Wang X, Berkovich A, Tsuriel S, Lichtman S, Elias E, Gomez J, Doroshow D, Smith C, Veluswamy R, Marron T, Rohs N, Mack P, Hirsch F, Rolfo C. cfDNA NGS for Identification of Primary and Acquired Resistance in Patients With Lung Cancer and EGFR Mutations. The Journal Of Liquid Biopsy 2023, 1: 100047. DOI: 10.1016/j.jlb.2023.100047.
- The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomasOffin M, Fitzgerald B, Zauderer M, Doroshow D. The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomas. Journal Of Cancer Metastasis And Treatment 2023, 9: null-null. PMID: 38895597, PMCID: PMC11185317, DOI: 10.20517/2394-4722.2022.140.
- Trastuzumab emtansine: determining its role in management of HER2+ breast cancerDoroshow DB, LoRusso PM. Trastuzumab emtansine: determining its role in management of HER2+ breast cancer. Future Oncology 2017, 14: 589-602. PMID: 29214842, DOI: 10.2217/fon-2017-0477.
- BET inhibitors: a novel epigenetic approachDoroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Annals Of Oncology 2017, 28: 1776-1787. PMID: 28838216, DOI: 10.1093/annonc/mdx157.
- Residential Treatment and the Invention of the Emotionally Disturbed Child in Twentieth-Century AmericaDoroshow DB. Residential Treatment and the Invention of the Emotionally Disturbed Child in Twentieth-Century America. Bulletin Of The History Of Medicine 2016, 90: 92-123. PMID: 27040027, DOI: 10.1353/bhm.2016.0023.
- Matthew Smith, An Alternative History of Hyperactivity: Food Additives and the Feingold DietDoroshow D. Matthew Smith, An Alternative History of Hyperactivity: Food Additives and the Feingold Diet. Social History Of Medicine 2012, 25: 884-885. DOI: 10.1093/shm/hks043.
- The Progressive Past of Residential Treatment of Emotionally Disturbed ChildrenDoroshow DB. The Progressive Past of Residential Treatment of Emotionally Disturbed Children. Pediatrics 2012, 129: 607-608. PMID: 22412024, DOI: 10.1542/peds.2011-2250.
- An alarming solution: Bedwetting, medicine, and behavioral conditioning in mid-twentieth-century America.Doroshow DB. An alarming solution: Bedwetting, medicine, and behavioral conditioning in mid-twentieth-century America. Isis 2010, 101: 312-37. PMID: 20718274, DOI: 10.1086/653095.
- Performing a Cure for Schizophrenia: Insulin Coma Therapy on the WardsDoroshow DB. Performing a Cure for Schizophrenia: Insulin Coma Therapy on the Wards. Journal Of The History Of Medicine And Allied Sciences 2006, 62: 213-243. PMID: 17105748, DOI: 10.1093/jhmas/jrl044.